Roadmap for an early gene therapy for cystic fibrosis airway disease

Area of Science:

• Pulmonary Medicine
• Genetics
• Biotechnology

Background:

• Gene therapy presents a mutation-independent strategy for treating cystic fibrosis (CF) airway disease.
• Preclinical efficacy studies in relevant models are crucial for developing clinical gene therapy candidates.
• Historically, the lack of appropriate animal models hindered CF airway pathology research.

Purpose of the Study:

• To review the development and utility of animal models for CF airway disease.
• To assess the potential of gene therapy for CF treatment.
• To highlight the importance of early intervention in CF gene therapy.

Main Methods:

• Review of scientific literature on CF animal models and gene therapy research.
• Analysis of preclinical data from various CF animal models (pig, ferret, rat).
• Discussion of the implications of CF lung pathology progression and treatment timing.

Main Results:

• Multiple CF animal models exhibiting CF airway disease hallmarks have been developed since 2008.
• These models facilitate efficacy testing of gene therapy beyond basic endpoints.
• Early treatment windows are critical due to progressive CF lung pathology.

Conclusions:

• Gene therapy holds significant potential to cure or treat CF airway disease, reducing patient burden.
• Availability of advanced animal models is key to advancing CF gene therapy clinical development.
• Newborn screening and prenatal diagnosis can facilitate timely, preventive gene-based treatments for CF.